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Phase III studies have demonstrated the clinical beneﬁt of adding neo-adjuvant androgen deprivation to radical radiotherapy
for clinically localised prostate cancer. We have developed a nomogram to describe the probability of PSA control for patients
treated in this way. Five hundred and seventeen men with clinically localised prostate cancer were treated with 3–6 months
of neo-adjuvant androgen deprivation and radical radiotherapy (64 Gy in 32#) between 1988 and 1998. Median presenting
PSA was 20 ng ml
71, and 56% of patients had T3/4 disease. Multivariate analysis of pre-treatment factors was performed, and
a nomogram developed to describe PSA-failure-free survival probability. At a median follow-up of 44 months, 233 men had
developed PSA failure. Presenting PSA, histological grade and clinical T stage were all highly predictive of PSA failure on
multivariate analysis. The nomogram score for an individual patient is given by the summation of PSA (510=0, 10–19=16,
20–49=44, 550=100), grade (Gleason 2–4=0, 5–7=44, 8–10=81) and T stage (T1/2=0, T3/4=35). For a nomogram
score of 0, 50, 100 and 150 points the 2 year PSA control rate was 93, 87, 75 and 54%, and the 5 year PSA control rate was
82, 67, 44 and 18%. These results are comparable to those using surgery or higher doses of radical radiotherapy alone. The
nomogram illustrates the results of multivariate analysis in a visually-striking way, and facilitates comparisons with other
treatment methods.
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Radical external beam radiotherapy is a recognised curative treat-
ment strategy for localised prostate cancer, and is given to
approximately 30% of men with newly diagnosed prostate cancer
in the USA (Mettlin et al, 1997). The outcome of radical radiother-
apy (RR), in terms of biochemical control, appears to be similar, in
comparable patients, to that of alternative treatment modalities,
such as radical prostatectomy (Zietman et al, 1994; D’Amico et
al, 1997; Keyser et al, 1997; Martinez et al, 2000) or brachytherapy
(D’Amico et al, 1998). However, disease recurrence after radical
treatment is common. Long term follow up studies have shown
actuarial PSA failure rates of 29% for T1 tumours, 46% for T2a,
and as high as 80% for T2b/c, T3 or T4 cancers (Hancock et al,
1995; Zietman et al, 1995).
The addition of neoadjuvant androgen deprivation (NAD) has
been proposed as a means of improving the outcome of radical
radiotherapy. As well as reducing the clinical target volume, which,
in combination with conformal radiotherapy planning techniques
(Shearer et al, 1992; Dearnaley et al, 1994; Zelefsky et al, 1994;
Forman et al, 1995), may aid safe radiation dose escalation (Yang
et al, 1995). NAD can also cause additional (or even synergistic)
tumour cell kill (Joon et al, 1997; Zietman et al, 1997). Three
randomised trials have shown that the addition of NAD to radical
external beam radiotherapy does indeed confer a beneﬁt, in terms
of local control, progression-free survival (Pilepich et al, 1995;
Laverdiere et al, 1997; Porter et al, 1997), and in the case of RTOG
8610, overall survival (Pilepich et al, 2001). These studies include a
combined total of just over 400 men treated with NAD and radical
radiotherapy. There are few other series of men treated in this way,
the largest being a report on 213 patients from Memorial Sloan–
Kettering (Zelefsky et al, 1998).
One of the problems complicating the clinical study of prostate
cancer, is the difﬁculty in comparing the results of different series.
Results may be inﬂuenced not just by treatment strategy, but also
by case mix, extent of staging procedures, length of follow-up and
criteria for determining PSA failure. A recent comprehensive review
of the radiotherapy literature found that the published series
differed markedly in terms of these factors, making meaningful
comparisons difﬁcult (Vicini et al, 1998). It might be more useful
to compare the outcome of individual subgroups, matched for
known prognostic factors, but unfortunately, there is no consensus
on the deﬁnition of such prognostic subgroups. The use of a
nomogram is one way of addressing this difﬁculty. A nomogram
can provide, in an easily accessible form, outcome data in terms
of biochemical control, for any given combination of prognostic
factors, and, if validated on a separate data set, can also be used
to predict the outcome of future patients treated in the same way.
Here, we present the largest series to date of men with clinically
localised prostate cancer treated with NAD and radical external
beam radiotherapy. These data have been used to produce the ﬁrst
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PATIENTS AND METHODS
Patient selection and investigation
Five hundred and seventeen men with histologically proven, clini-
cally localised prostate cancer, treated at the Royal Marsden
Hospital between 1988 and 1998, received NAD and radical exter-
nal beam radiotherapy, and are included in this study. All patients
gave informed consent prior to commencement of treatment. Pre-
treatment investigations included clinical examination, full blood
count, serum creatinine and electrolytes, serum PSA measurement,
CT or MRI scan of pelvis, bone scan, P-A chest radiograph, and
prostatic sextant biopsies or TURP. Pelvic lymph node sampling
was not performed. All biopsy specimens were reviewed at the
Royal Marsden Hospital. Men were included if they had T1–4,
N0, M0 disease, regardless of presenting PSA, and had no signiﬁ-
cant co-morbidities, such that they were considered to have a life
expectancy of at least 5 years. Radical prostatectomy would have
been considered by referring urologists for the minority of patients
with suitable cancers, but during the time course of this study radi-
cal radiotherapy following NAD has remained the preferred radical
option for most patients (Savage et al, 1997; Donovan et al, 1999).
‘Watchful waiting’ or androgen deprivation alone were used in
men for whom radical treatment options were considered inap-
propriate or who preferred a non-radical treatment approach.
The study period spanned two distinct methods of histological
assessment. One hundred and ninety-ﬁve cases, examined during
the earlier years of the study, were classed as well, moderately or
poorly differentiated according to the WHO system. Of the
remainder, 299 cases were graded by the Gleason system, while
23 cases had no Gleason score or grading available. For the
purposes of the current study, well differentiated tumours were
grouped with Gleason scores 2–4, moderately differentiated
tumours with Gleason scores 5–7 and poorly differentiated
tumours with Gleason scores 8–10. Patient characteristics are
listed in Table 1.
Treatment protocol
Androgen deprivation was achieved by an initial 3 week course
of cyproterone acetate, 100 mg tds orally, together with monthly,
subcutaneous leuprorelin 3.75 mg or goserelin 3.6 mg, starting 1
week after cyproterone, and continuing until the completion of
radiotherapy. Radical radiotherapy was intended to commence
after 3 months of androgen deprivation, but longer courses of
initial hormone treatment were allowed for men with bulky local
disease, obstructive urinary symptoms, or occasionally when there
was uncertainty over the interpretation of initial staging investi-
gations. The median time from starting androgen deprivation to
radiotherapy was 111 days (inter-quartile range 97 to 141 days).
Adjuvant hormone therapy following radiotherapy was not used.
Men were treated supine, with a full bladder. Thirty men were
treated in a trial using a pelvic immobilisation device, while
for the remainder footstocks alone were used. The planning
target volume (PTV) included the prostate gland with a margin
of 1 or 1.5 cm, and was localised using CT planning. The semi-
nal vesicles were included in the PTV in men with T3 disease,
poorly differentiated (Gleason score 8–10) tumours, or with a
presenting PSA of 420 ng ml
71. Men were treated with an
anterior ﬁeld and two wedged lateral or postero-lateral ﬁelds,
using 6–10 MV photons (Dearnaley et al, 1999). Conformal
shielding was evaluated in a randomised trial until January
1995 (Dearnaley et al, 1999), and then adopted during the
remaining study period. The planned dose was 64 Gy, speciﬁed
at the intersection of the treatment beams, delivered in 2 Gy
fractions, ﬁve times a week, over 6½ weeks. Fourteen patients,
treated in the early years of the study, received 60 Gy in 30 frac-
tions.
Follow-up
Men were seen 6 weeks after starting neoadjuvant hormones,
immediately pre-radiotherapy, and on alternate weeks during
radiotherapy. They were then followed at 3 to 6 month intervals
for 2 years, and annually thereafter. Follow-up included clinical
examination and serum PSA measurement, but not routine
imaging. Bone scan and CT scan of the abdomen and pelvis was
performed if there was clinical suggestion of recurrent disease, or
if the PSA was both more than 50% of the presenting PSA, and
greater than 10 ng ml
71. Continuous, long term androgen depriva-
tion, with either bilateral orchidectomy or LHRH agonist, was
started either at the time of PSA failure, or delayed until sympto-
matic progression, according to the individual preference of the
patient and clinician. The Hybritech enzyme immunoassay and
the Roche immunometric assay used prior to 1997 provided results
to the nearest nanogram per ml, with a lower limit of detection of
1n gm l
71. In January 1997, the Abott AXSYM assay was adopted,
with a lower limit of 0.1 ng ml
71. Given the limitations of the
assays used during the earlier years of the study, we deﬁned
biochemical failure as either two consecutive rises in PSA
42n gm l
71, or the commencement of androgen deprivation.
The date of PSA failure was taken as the date of the ﬁrst PSA value
42n gm l
71, or the date of starting androgen deprivation, respec-
tively.
Statistical methods
Univariate survival analysis of the time to PSA failure was
performed using the Kaplan–Meier product limit method (Kaplan
and Meier, 1958). Prognostic groups were compared using the log-
rank test (Peto and Peto, 1972). Factors with a P-value of less than
0.05 were considered signiﬁcant and were subsequently entered
into the multivariate analysis.
The multivariate model was generated using the Cox propor-
tional hazards model (Cox and Oakes, 1984). A P-value of 0.05
was used as the criterion to enter or remove variables from the
stepwise model. The covariates in the model were organised such
that a high relative risk of PSA failure corresponded to a hazard
ratio of greater than 1. All variables in the ﬁnal model were
grouped into categories. No continuous variables were used in
the ﬁnal model.
C
l
i
n
i
c
a
l
Table 1 Characteristics of the study group
Median age 69 years (range 49 to 83)
T stage Cases (%)
T1 37 (7.2)
T2 169 (32.7)
T3 267 (51.6)
T4 24 (4.6)
n/k 20 (3.9)
Presenting PSA
0–10 102 (19.7)
10–20 135 (26.1)
20–50 147 (28.4)
450 88 (17.0)
n/k 45 (8.7)
Grade
GL 2,3,4/well 70 (13.5)
GL 5,6,7/mod 326 (63.1)
GL 8,9,10/poor 98 (19.0)
n/k 23 (4.4)
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generated in the model for each prognostic factor (i.e. log of the
hazard ratio) onto a linear scale with a maximum based on the
maximum coefﬁcient (PSA 450) assuming the value of 100 points.
All coefﬁcients for each prognostic group were then plotted relative
to this maximum. This allowed easy summation of the risks for any
combination of prognostic groups. The total points for a particular
patient could then be plotted against the conversion graph to esti-
mate the probability of remaining free from PSA failure for a
patient with that particular prognostic group pattern.
The conversion graph was generated from the PSA failure-free
survivor function for the baseline covariate pattern. This baseline
survivor function was then used to calculate the 1, 2, 3, 4 and 5
year baseline PSA failure-free survival probabilities. The hazards
for each prognostic factor from the nomogram were then calcu-
lated for all possible covariate patterns and converted to total
hazard ratios (relative to the baseline covariate pattern). The PSA
failure-free survival probabilities for each of years 1, 2, 3, 4 and
5 were then raised to the power of the total hazard ratios for each
covariate pattern to calculate the PSA failure-free survival for each
covariate pattern for each year. These were then plotted against the
total points corresponding to the relevant covariate pattern from
the nomogram. The mean standard error of the PSA failure free
survival function for each of the years 1 to 5 was used to estimate
the 95% CI of the PSA failure free survival estimate from the
nomogram for each year.
RESULTS
Five hundred and seventeen men with clinically localised prostate
cancer were treated with neoadjuvant androgen deprivation and
radical radiotherapy. At a median follow-up of 44 months, 233
men developed PSA failure, of whom 20 commenced androgen
deprivation on the clinical suspicion of tumour recurrence, without
having fulﬁlled the biochemical criteria for failure. Overall freedom
from PSA failure was 68, 56 and 41% at 2, 3 and 5 years, respec-
tively.
Clinical T stage, grade, presenting PSA, and pre-radiation PSA
were all highly signiﬁcant (P50.001) predictors of PSA failure
on univariate analysis (Table 2). Age was also signiﬁcant, with
older patients faring better than younger, but this effect was less
pronounced (P=0.025). On multivariate analysis (Table 3), clinical
T stage, grade, presenting PSA and age, but not pre-radiation PSA,
were found to be independent prognostic factors for freedom from
PSA failure. The results of multivariate analysis of factors predict-
ing for freedom from PSA failure were then displayed in the form
of a nomogram (Figures 1 and 2), from which the freedom from
PSA failure at 1, 2, 3, 4 and 5 years may be identiﬁed for any
combination of prognostic factors. For example, a man with Glea-
son score 6, clinical stage T2 prostate cancer with a presenting PSA
of 15 ng ml
71, has a nomogram score of 60 (44+0+16) points,
giving a 5 year freedom from PSA failure of 64%, whereas a
man with the same presenting PSA, but with Gleason score 8, clin-
ical stage T3 disease, has a nomogram score of 132 points
(81+35+16), and therefore a 5 year freedom from PSA failure of
28%.
Although age was a signiﬁcant predictor of PSA failure-free
survival on multivariate analysis, it was not incorporated into the
nomogram in view of the small magnitude of its effect (approxi-
mately 4% difference in 5 year freedom from PSA failure,
comparing above and below the median age), and in order to facil-
itate comparisons with other series in which age was not found to
be a signiﬁcant predictor.
The 95% CI of the estimate of freedom from PSA failure was
calculated for each of the years 1, 2, 3, 4 and 5 as +3.6%,
+4.4%, +4.8%, +5.1% and +5.8% respectively. The freedom
from PSA failure estimates should therefore be considered to be
accurate to within +5%.
DISCUSSION
This is the largest study to date of men with clinically localised
prostate cancer treated with neoadjuvant androgen deprivation
and radical radiotherapy. We have described the outcome in terms
of freedom from PSA failure, and have generated a pre-treatment
nomogram incorporating the results of multivariate analysis, which
describes that outcome for any combination of prognostic factors.
The major prognostic contribution of presenting PSA and grade,
and the relatively minor contribution of clinical T stage are readily
apparent when the data is displayed in this way.
Similar nomograms which have been developed to describe the
outcome of men with localised prostate cancer have been catalo-
gued by Ross et al (2001). The Memorial Sloan–Kettering
nomogram for predicting the outcome of conformal radiotherapy
is particularly noteworthy (Kattan et al, 2000). Merits of this
nomogram are that it was based on a series of over 1000 patients,
validated on a separate data set, and that it included both radiation
dose and use of NAD as predictor variables. It differs from our
nomogram in several important ways. First, the population on
C
l
i
n
i
c
a
l
Table 2 Univariate analysis of factors inﬂuencing freedom from PSA
failure
Per cent 3 year freedom
Factor Cases from PSA failure P-value
T stage
T1 36 82.3
T2 166 67.3 50.001
T3 265 46.3
T4 24 55.6
Presenting PSA
0–10 101 70.1
10–20 131 70.3 50.001
20–50 145 56.2
450 88 24.4
Grade
GL 2,3,4/well 69 75.4
GL 5,6,7/mod 321 59.5 50.001
GL 8,9,10/poor 96 33.1
Age
569 years 252 51.1 0.025
4=69 years 257 59.8
Pre-RT PSA
52 269 65
2–4 114 48.7 50.001
44 95 36.5
Table 3 Multivariate analysis of factors inﬂuencing freedom from PSA
failure
Hazard Standard
Factor Group ratio error 95% CI P-value
T stage T1/T2
T3/T4 1.65 0.17 1.19–2.28 0.03
Presenting PSA 510
10–20 1.25 0.25 0.76–2.05 0.38
20–50 1.88 0.23 1.2–2.94 0.006
450 4.197 0.24 2.64–6.08 50.0001
Grade GL 2,3,4/well
GL 5,6,7/mod 1.87 0.27 1.06–3.17 0.02
GL 8,9,10/poor 3.19 0.29 1.796–5.646 0.0001
Age 569 years 1.47 0.15 1.10–1.97 0.009
4=69 years
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British Journal of Cancer (2002) 86(5), 686–691 ã 2002 Cancer Research UKwhich it was based consisted largely of screen-detected early pros-
tate cancer, with a median PSA of 11 ng ml
71 (c.f. 20 ng ml
71 in
the current series), and with 77% (c.f. 45%) having T1/T2 disease.
Second, the median radiation dose was 75.6 Gy in 42 fractions,
compared with 64 Gy in 32 fractions. Third, the ASTRO consensus
deﬁnition of PSA failure was used. So, while nomograms may
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Figure 1 Nomogram: the points for each of the three prognostic factors may be calculated from this nomogram by reading off the x-axis values (e.g. T3
tumours score 35 points). The sum of the points for all three prognostic factors is used in the PSA failure conversion graph (Figure 2) to estimate the per
cent free from PSA failure at various time points.
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Figure 2 PSA failure conversion graph: The sum of the points from the three prognostic factors (from Figure 1) should be taken on the x-axis and then
the percentage of patients free from PSA failure at years 1 to 5 may be read off the y-axis (e.g. for a total points 60 points will have a 5 year freedom from
PSA failure rate of 64%).
Biochemical control in prostate cancer
CC Parker et al
689
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 686–691make it easier to compare the results from different centres, they
must still be interpreted cautiously, and do not obviate the need
for appropriately designed phase III studies.
With these reservations in mind, in our study, the 5 year prob-
ability of freedom from PSA failure for a man with a Gleason 6,
clinical stage T2 prostate cancer and a presenting PSA of
15 ng ml
71 is 64% (95% CI 59–69%). This compares with a
probability of 40–72%, depending on RT dose, according to the
Memorial Sloan–Kettering nomogram discussed above (Kattan et
al, 2000), and of 55–75% according to Kattan’s pre-operative
surgical nomogram (Kattan et al, 1998). For a Gleason 8, clinical
stage T3 tumour with a PSA of 15 ng ml
71, the 5 year probability
of freedom from PSA failure in our series is 28% (95% CI 23–
33%), compared with approximately 15–53%, depending on RT
dose, according to the Memorial Sloan–Kettering nomogram
(Kattan et al, 2000).
The results of our study conﬁrm, in men treated with neoadju-
vant androgen deprivation and radical radiotherapy, the utility of
the prognostic factors which are known to be important for men
treated either with radiotherapy alone, or with radical prostatect-
omy, namely, clinical T stage, grade and presenting PSA. In
addition, and more surprisingly, age was found to be an indepen-
dent prognostic factor, with patients younger than 69 years having
a signiﬁcantly poorer outcome than those older than 69 years. A
recent comprehensive review of the effect of age on the outcome
of localised prostate cancer concluded that age at diagnosis is not
a signiﬁcant determinant of outcome for men treated either with
radiation alone or with radical prostatectomy (Parker et al,
2001). Our data based on men receiving combined radiation and
hormonal therapy generates the hypothesis of a treatment-speciﬁc
effect of age on outcome. The rate and extent of testosterone
recovery after stopping LHRH therapy is age-dependent (Oefelein,
1998), and this could explain the earlier detection of biochemical
failure in younger men. RTOG 9202 demonstrated that the dura-
tion of testosterone suppression can inﬂuence outcome, not just
in terms of biochemical control, but also in terms of cause-speciﬁc
survival (Hanks et al, 2000). Although the beneﬁts of neoadjuvant
androgen deprivation have been well established in phase III trials
(Pilepich et al, 1995, 2001; Laverdiere et al, 1997; Porter et al,
1997), the possibility that the magnitude of this beneﬁt is age-
dependent should be tested by subgroup analysis of these studies.
Data concerning the androgen-dependent Shionogi adenocarci-
noma in nude mice, which serves as an animal model for
prostate cancer, suggests that a good response to neoadjuvant
androgen deprivation, deﬁned as a volume reduction of greater
than 50%, predicts for improved tumour control following radio-
therapy (Zietman et al, 1997). This is somewhat analagous to the
clinical ﬁndings of Zelefsky et al (1998), who in their study of
213 men with clinically localised prostate cancer, found that a
pre-radiation PSA of 50.5 ng ml
71 following neoadjuvant andro-
gen deprivation was an independent favourable prognostic factor.
We attempted to address this issue by testing the PSA measured
immediately pre-radiotherapy as a possible predictive factor for
biochemical control. While the pre-radiotherapy PSA correlates
signiﬁcantly with outcome in terms of freedom from PSA failure
on univariate analysis (Table 2), it also correlates with presenting
PSA, and is no longer statistically signiﬁcant on multivariate analy-
sis. The discrepancy between our ﬁndings and those of Zelefsky et
al (1998) could reﬂect differences in the study populations, or the
relative insensitivity of the PSA assay used in the early part of our
series.
This study started recruiting in 1988, enabling us to gather the
largest series to date of men with clinically localised prostate cancer
treated with neoadjuvant androgen deprivation and radical radio-
therapy. However, certain aspects of patient management in the
earlier part of the study would no longer be regarded as state of
the art. First, although Gleason scoring is now widely accepted as
the most informative method of grading prostate cancer, it became
standard practice at the Royal Marsden Hospital only after the start
of this series. We have not re-examined the specimens graded using
the previous WHO system, which classiﬁed cases into three levels
of differentiation, but rather have assumed that these three cate-
gories correspond to certain Gleason score groupings. Second,
our deﬁnition of PSA failure (two consecutive rising PSA levels
42n gm l
71, dated from the ﬁrst PSA level 42n gm l
71) was
constrained by the limited sensitivity of the assays used in the
majority of this study. In the future we shall compare with the
ASTRO consensus deﬁnition of failure (ASTRO, 1997) (three
consecutive rises in PSA dated midway between the nadir and ﬁrst
rising level) in patients who have been followed with more sensitive
assays. This would show the magnitude of any time lag in deﬁni-
tion of time to failure. However it should be remembered that the
consensus deﬁnition was suggested for patients treated with radio-
therapy alone, and the pattern of PSA change after neoadjuvant
androgen deprivation and radiotherapy, which depends in part
on recovery of testosterone levels, may need further study. Third,
our series consists largely of men presenting clinically, rather than
with screen detected prostate cancer. The consequent large propor-
tion of men with locally advanced tumours, and high presenting
PSA, means that one should be cautious in applying our results
to asymptomatic, early cancers. However, it also means that our
series is entirely representative of the typical case-mix seen in the
UK today.
Recently completed randomised trials in localized prostate cancer
have shown beneﬁts for both radiation dose escalation (Pollack et
al, 2000; Dearnaley et al, 2001), and for the use of long-term adju-
vant androgen deprivation in addition to NAD (Hanks et al, 2000).
Those men at greatest risk of local rather than metastatic failure
may beneﬁt most from radiation dose escalation, whereas men
more liable to distant failure may be better served by adjuvant
hormonal treatment. A future report will seek to deﬁne these cate-
gories for our series of patients. Both of these approaches to
intensifying treatment can be expected to carry greater morbidity
compared with conventional methods. Do our results permit the
identiﬁcation of a group of men with a sufﬁciently good outcome
that they could be spared the potential extra morbidity associated
with these more intensive treatments? For the most favourable
group of patients (men with Gleason score 2–4, clinical stage T1/
T2 prostate cancers with a presenting PSA of less than 10 ng ml
71),
5 year biochemical control was only 82.5%. Even for this group,
results could be signiﬁcantly improved, and they are suitable candi-
dates for phase III trials of treatment intensiﬁcation.
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